Jan Libiger

Jan Libiger

Auto-generated profile, based on publicly available information

Jan Libiger

Psychiatric Clinic, Faculty Hospital Hradec Králové, Charles University Medical School, Hradec Králové, Czech Republic

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in The Lancet
Verified
Journal Article
Closed access
RKRené S Kahn
René S Kahn
WFW Wolfgang Fleischhacker
W Wolfgang Fleischhacker
HBHan Boter
Han Boter
MDMichael Davidson
Michael Davidson
YVYvonne Vergouwe
Yvonne Vergouwe
DGDiederick E Grobbee
Diederick E Grobbee

1 June 2009 in American Journal of Psychiatry
Verified
Journal Article
Closed access
PDF file
MDMichael Davidson
Michael Davidson
SGSilvana Galderisi
Silvana Galderisi
MWMark Weiser
Mark Weiser
NWNomi Werbeloff
Nomi Werbeloff
WFWolfgang W. Fleischhacker
Wolfgang W. Fleischhacker
RKRené S. Kahn
René S. Kahn

1 March 2013 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
SGSilvana Galderisi
Silvana Galderisi
Armida MucciArmida Mucci
Armida Mucci
BIBitter Istvan
Bitter Istvan
JLJan Libiger
Jan Libiger
PBPaola Bucci
Paola Bucci
FGfor the EUFEST Study Group
for the EUFEST Study Group

1 December 2009 in Schizophrenia Research
Verified
Journal Article
Closed access
SGSilvana Galderisi
Silvana Galderisi
MDMichael Davidson
Michael Davidson
RKRené S Kahn
René S Kahn
Armida MucciArmida Mucci
Armida Mucci
HBHan Boter
Han Boter
EGEUFEST group
EUFEST group

1 December 2009 in Schizophrenia Research
Verified
Journal Article
Closed access
HBHan Boter
Han Boter
JPJoseph Peuskens
Joseph Peuskens
JLJan Libiger
Jan Libiger
WFW Wolfgang Fleischhacker
W Wolfgang Fleischhacker
MDMichael Davidson
Michael Davidson
EGEUFEST study group
EUFEST study group

1 November 2002 in European Psychiatry
Verified
Journal Article
Closed access
LHLadislav Hosák
Ladislav Hosák
JLJ. Libiger
J. Libiger
Summary: The first choice group of psychotropic agents in schizophrenia is neuroleptics. However, this treatment is not effective in all patients and with every symptom. We summarize papers published on the role of antiepileptic drugs in treatment-resistant schizophrenia. We have searched the computer database system MEDLINE for relevant articles including reviews, reports of drug studies and case histories. Antiepileptic drugs can change symptoms of schizophrenia by their action on GABA-ergic neurotransmission or via anti-glutamatergic mechanisms. High doses of adjunctive benzodiazepines reduce positive symptoms, anxiety, and agitation. Carbamazepine is effective in affective symptoms of schizophrenia and influences violent behavior in psychotic patients. Its anti-kindling action may represent a promising treatment strategy for some patients with chronic course of schizophrenia. Valproate treatment leads to a decrease in positive symptoms as well as hostility. Lamotrigine is expected to influence the positive, negative, affective, and cognitive symptoms of schizophrenia. New antiepileptics (e.g., gabapentin, oxcarbazepine, topiramate, vigabatrin) present a promise as potential adjuncts to neuroleptic treatment in resistant symptoms of schizophrenia.